2020-11-13T12:38:51-06:00 2019-12-31 131639826 EISNERAMPER LLP 130 NORTH 18TH STREET SUITE 3000 PHILADELPHIA PA 191032757 990 2019-01-01 232213205 NATIONAL DISEASE RESEARCH INTERCHANGE NATI 2155577361 1601 CHERRY ST SUITE 1700 PHILADELPHIA PA 19102 WILLIAM LEINWEBER PRESIDENT 2155577361 2020-10-19 1 HELEN M MARTIN P01330899 2158818800 64.238.150.4 2020-10-19 15:30:44 ED P DA39A3EE5E6B4B0D3255BFEF95601890AFD80709 0EDE4F5BE59FB99924CAAEE7408372872BC47088 2019 2021-01-29 14:40:06Z X WILLIAM LEINWEBER 1601 CHERRY ST SUITE 1700 PHILADELPHIA PA 19102 7121789 0 X WWW.NDRIRESOURCE.ORG X 1988 PA ADVANCING THE PROCUREMENT, PRESERVATION AND DISTRIBUTION OF HUMAN CELLS, TISSUES AND ORGANS FOR BIOMEDICAL RESEARCH, NATIONALLY AND INTERNATIONALLY. 16 15 54 0 0 0 2300789 1921484 5147356 5188760 5735 11545 -45430 0 7408450 7121789 0 0 0 0 3667058 3586844 0 0 0 3555329 3627938 7222387 7214782 186063 -92993 3796622 6065530 961504 3323405 2835118 2742125 ADVANCING THE PROCUREMENT, PRESERVATION AND DISTRIBUTION OF HUMAN CELLS, TISSUES AND ORGANS FOR BIOMEDICAL RESEARCH. 0 0 2192592 1069538 HUMAN TISSUE AND RESOURCE FOR RESEARCH: NDRI RECEIVED A FEDERAL AWARD FOR THE HUMAN TISSUE AND ORGAN RESOURCE FOR THE PROCUREMENT AND DISTRIBUTION OF NORMAL AND DISEASED HUMAN ORGANS AND TISSUES TO ADVANCE BIOMEDICAL SCIENCE. 605707 2866892 PARTNER PROGRAM: COORDINATES VARIOUS HUMAN ORGAN AND TISSUE PROCUREMENT PROGRAMS WITH THE PHARMACEUTICAL AND BIOTECHNOLOGY INDUSTRIES TO ACCELERATE RESEARCH AND DEVELOPMENT. SEVERAL OF THESE PROGRAMS HAVE LED TO THE DEVELOPMENT OF TREATMENTS FOR MEDICAL CONDITIONS SUCH AS LUNG DISEASE, DIABETES, AND CANCER, TO NAME ONLY A FEW. OTHER PARTNER PROGRAMS HAVE LED TO THE CREATION OF RESEARCH TOOLS FOR USE IN NUMEROUS TOXICOLOGY AND DRUG DISCOVERY PLATFORMS. 2170664 1252330 RESEARCH COLLABORATIONS WITH FOUNDATION AND PATIENT ADVOCACY GROUPS (PAG): NDRI MAINTAINS COLLABORATIONS WITH A VARIETY OF DIFFERENT FOUNDATION AND PATIENT ADVOCACY GROUPS FOCUSED ON THE ADVANCEMENT OF RESEARCH IN EACH OF THEIR RESPECTIVE AREAS OF INTEREST. THESE COLLABORATIONS BRING TOGETHER PATIENTS, PAGS, FOUNDATIONS, NDRI AND THE PHARMACEUTICAL INDUSTRY TO HELP ADVANCE R&D UTILIZING CRITICAL HUMAN BIOSPECIMENS GIFTED BY PATIENTS/DONORS. 4968963 1 1 0 1 0 0 0 0 0 0 1 0 0 0 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 43 0 1 54 1 0 0 0 0 0 0 0 0 0 0 0 0 X 16 15 0 0 0 0 0 0 0 1 1 0 0 1 1 1 1 1 1 1 1 0 PA X ROBERT ZIPPERLEN CFO 2155577361 1601 CHERRY ST SUITE 1700 PHILADELPHIA PA 19102 WILLIAM LEINWEBER PRESIDENT & CEO 35.00 X X 340644 0 28286 GENE C KOPEN SENIOR VP, STRATEGIC INITIATIVES 35.00 X 193649 0 38463 THOMAS BELL VICE PRESIDENT, OPERATIONS 35.00 X 157348 0 7703 ROBERT ZIPPERLEN VP ADMINISTRATION & CFO 35.00 X 98111 0 17293 MARY JC HENDRIX CHAIR OF THE BOARD 1.00 X X 0 0 0 HAL E BROXMEYER CHAIRMAN EMERITUS 1.00 X 0 0 0 MEENHARD HERLYN CHAIRMAN EMERITUS 1.00 X 0 0 0 DAVID M ALBERT BOARD MEMBER 1.00 X 0 0 0 SHAWN BLACKBURN BOARD MEMBER 1.00 X 0 0 0 SULAYMAN DIB-HAJJ BOARD MEMBER 1.00 X 0 0 0 MEGAN KASIMATIS SINGLETON BOARD MEMBER 1.00 X 0 0 0 VERA KRYMSKAYA BOARD MEMBER 1.00 X 0 0 0 ROBERT MARCANTUONO BOARD MEMBER 1.00 X 0 0 0 JESSICA MULHOLLAND BOARD MEMBER 1.00 X 0 0 0 HOWARD M NATHAN BOARD MEMBER 1.00 X 0 0 0 LOUIS PHILIPSON BOARD MEMBER 1.00 X 0 0 0 ARTHUR H RUBENSTEIN BOARD MEMBER 1.00 X 0 0 0 JIM VAUGHT BOARD MEMBER 1.00 X 0 0 0 MICHAEL WHITE BOARD MEMBER 1.00 X 0 0 0 789752 0 91745 3 0 1 0 CAPGEMINI AMERICA INC 79 FIFTH AVENUE 3RD FLOOR NEW YORK NY 10003 CONSULTING SERVICES 865674 CONNECTLIFE (UPSTATE NEW YORK TRANSPLANT 4444 BRYANT AND STRATTON WAY WILLIAMSVILLE NY 142216013 ORGAN/TISSUE PROCUREMENT 203713 LIFENET HEALTH PO BOX 79636 BALTIMORE MD 212790636 ORGAN/TISSUE PROCUREMENT 168502 CENTER FOR ORGAN RECOVERY & EDUCATION 204 SIGMA DRIVE PITTSBURG PA 152382825 ORGAN/TISSUE PROCUREMENT 141335 THE TRUSTEES OF COLUMBIA UNIVERSITY 21 AUDUBON AVE 2ND FLOOR SUITE 20 NEW YORK NY 100324220 ORGAN/TISSUE PROCUREMENT 118252 5 1921484 1921484 RESEARCHER FEES 900099 3554579 3554579 CORPORATE CONTRACTS 900099 1620511 1620511 GOVERNMENT CONTRACT 900099 13670 13670 5188760 11545 11545 7121789 5188760 0 11545 484334 484334 2512247 1962475 549772 51923 35120 16803 337331 292545 44786 201009 135960 65049 10440 10440 7722 7722 41000 41000 10491 10491 59508 1350 58158 76415 31683 44732 217082 32079 185003 271100 271100 310921 209918 101003 83131 83131 77536 77536 BIOMATERIAL PROCUREMENT 1295961 1295961 REMOTE SITES 394252 394252 SHIPPING AND DELIVERY 355076 355076 LABORATORY 193095 193095 224208 29449 194759 7214782 4968963 2245819 0 500 500 1016892 822071 1844374 2392559 44910 44910 213864 205328 4188788 1588626 676082 2600162 3796622 6065530 479771 1304132 115269 122131 250000 1093700 116464 803442 961504 3323405 X 2835118 2742125 2835118 2742125 3796622 6065530 -92993 0 X 0 1 X 1 1 1 X 1791767 2157899 2385300 2300789 1921484 10557239 1791767 2157899 2385300 2300789 1921484 10557239 10557239 1220 1632 2115 5735 11545 22247 10579486 0.99790 0.99830 X RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 7214782 7214782 510739 127685 0 0 569190 509004 511119 510739 2100052 3150078 75576 25351 100927 142298 127251 127780 127685 525014 787521 762333 7349 754984 3426455 1581277 1845178 2600162 UNEXPENDED FEDERAL PROGRAM INCOME 99563 DEFERRED RENT CREDIT 703879 803442 X 7162199 40410 40410 7121789 0 7121789 7255192 40410 40410 7214782 0 7214782 PART X, LINE 2: THE INTERNAL REVENUE SERVICE HAS CLASSIFIED NDRI AS EXEMPT FROM FEDERAL INCOME TAXES UNDER SECTION 501(C)(3) OF THE INTERNAL REVENUE CODE ("CODE"), AS AN ORGANIZATION, CONTRIBUTIONS TO WHICH ARE DEDUCTIBLE UNDER SECTION 170(C) OF THE CODE, AND AS AN ORGANIZATION THAT IS NOT A PRIVATE FOUNDATION AS DEFINED IN SECTION 509(A) OF THE CODE. THEREFORE, NO PROVISION FOR INCOME TAXES HAS BEEN INCLUDED IN THESE FINANCIAL STATEMENTS. MANAGEMENT HAS EVALUATED THE TAX POSITIONS TAKEN BY NDRI, AND HAS CONCLUDED THAT AS OF DECEMBER 31, 2019 AND 2018, THERE ARE NO UNCERTAIN TAX POSITIONS TAKEN OR EXPECTED TO BE TAKEN THAT WOULD REQUIRE RECOGNITION OF A LIABILITY OR DISCLOSURE IN THE FINANCIAL STATEMENTS. NDRI RECOGNIZES ACCRUED INTEREST AND PENALTIES ASSOCIATED WITH UNCERTAIN TAX POSITIONS, IF ANY. THERE WERE NO INCOME TAX RELATED INTEREST OR PENALTIES RECORDED FOR EITHER OF THE YEARS ENDED DECEMBER 31, 2019 OR 2018. X X X 0 0 0 0 0 0 0 0 0 WILLIAM LEINWEBER PRESIDENT & CEO 340644 0 0 0 0 0 0 0 28286 0 368930 0 0 0 GENE C KOPEN SENIOR VP, STRATEGIC INITIATIVES 193649 0 0 0 0 0 8422 0 30041 0 232112 0 0 0 THOMAS BELL VICE PRESIDENT, OPERATIONS 157348 0 0 0 0 0 6893 0 810 0 165051 0 0 0 FORM 990, PART VI, SECTION B, LINE 11B AFTER THE FORM 990 HAS BEEN PREPARED BY THE INDEPENDENT ACCOUNTANTS, IT IS REVIEWED BY THE CFO AND THE PRESIDENT. THE FORM 990 IS THEN DISTRIBUTED TO THE BOARD OF DIRECTORS FOR REVIEW PRIOR TO SUBMISSION. FORM 990, PART VI, SECTION B, LINE 12C NDRI HAS A CONFLICT OF INTEREST POLICY FOR ALL BOARD MEMBERS AND SENIOR STAFF. ALL BOARD MEMBERS AND SENIOR STAFF ARE REQUIRED TO DISCLOSE ANY KNOWN CONFLICTS ON AN ANNUAL BASIS. FORM 990, PART VI, SECTION B, LINE 15 LETTER OF ACCOMPLISHMENTS AND RECOMMENDED INCREASE FOR THE PRESIDENT IS REVIEWED AND DECIDED UPON BY THE COMPENSATION COMMITTEE. FORM 990, PART VI, SECTION C, LINE 19 THE ORGANIZATION'S GOVERNING DOCUMENTS AND FINANCIAL STATEMENTS ARE MADE AVAILABLE TO THE PUBLIC UPON REQUEST.